Entry |
|
Name |
Mutation-activated RET to PI3K signaling pathway
|
Definition |
RET* -> PI3K -> PIP3 -> AKT -> MTOR |
Expanded |
5979v2 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475 |
Class |
|
Type |
Variant
|
Disease |
|
Gene |
5979 | RET; ret proto-oncogene |
5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
207 | AKT1; AKT serine/threonine kinase 1 |
208 | AKT2; AKT serine/threonine kinase 2 |
10000 | AKT3; AKT serine/threonine kinase 3 |
2475 | MTOR; mechanistic target of rapamycin kinase |
|
Variant |
|
Metabolite |
C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
Reference |
|
Authors |
Giunti S, Antonelli A, Amorosi A, Santarpia L |
Title |
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. |
Journal |
|
Reference |
|
Authors |
Ceolin L, Duval MADS, Benini AF, Ferreira CV, Maia AL |
Title |
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. |
Journal |
|
Reference |
|
Authors |
Arighi E, Borrello MG, Sariola H |
Title |
RET tyrosine kinase signaling in development and cancer. |
Journal |
|
LinkDB |
|